Advertisement

Topics

Latest "informed horizons" News Stories

13:34 EDT 26th April 2018 | BioPortfolio

Here are the most relevant search results for "informed horizons" found in our extensive news archives from over 250 global news sources.

More Information about informed horizons on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about informed horizons for you to read. Along with our medical data and news we also list informed horizons Clinical Trials, which are updated daily. BioPortfolio also has a large database of informed horizons Companies for you to search.

Showing "informed horizons" News Articles 1–25 of 4,200+

Relevant

Tetra Bio-Pharma (TSXV:$TBP.V) (OTCQB: $TBPMF) Added to Leading #Cannabis #ETF: Horizons Marijuana Life Sciences Index

OTTAWA, ONTARIO - March 20, 2018 (Investorideas.com Newswire) Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has been added to the Horizons Marijuana Life Sciences Index (HMMJ) managed by Horizons ETFs Management (Canada) Inc.


Five most-watched video perspectives

Live video perspectives from ophthalmology meetings give viewers the opportunity to hear a condensed version of speakers’ presentations.So far in 2018, Healio.com/OSN has attended Hawaiian Eye 2018 and Retina 2018, the Glaucoma 360: New Horizons Forum and the European Society of Cataract and Refractive Surgeons winter meeting to interview physicians regarding their presentations.Here are the top...

Horizons Launches New Marijuana ETF on NEO

The NEO Exchange (“NEO”) is pleased to announce that Horizons ETFs Management (Canada) Inc. (“Horizons ETFs”) launched the Horizons Emerging Marijuana Growers Index ETF on NEO today. With the launch of this new ETF, represented by the ticker HMJR, Horizons ETFs


Company Profile for Bright Horizons Family Solutions

Bright Horizons Family Solutions® is a leading provider of high-quality child care, early education and other services designed to help employers and families better address the challenges of work and family life. The Company provides full service center-based child care, back-up dependent care and educational advisory services to more than 1,100 clients ...

Protalix BioTherapeutics Announces Presentation to be made at the New Horizons in Fabry Disease Conference

CARMIEL, Israel, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) announced today two-year results from the phase I/II open-label extension clinical trial of pegunigalsidase alfa, or PRX-102, for the treatment of Fabry disease will be presented at the New Horizons in Fabry Disease Conference taking place November 24-25 in Prague, Czech Republic. ...

Protalix BioTherapeutics Presents Positive Results from the Phase I/II Open-Label Extension Trial for PRX-102 at the New Horizons for Fabry Disease Conference

Continued to Demonstrate Improvement across all Key Fabry Disease Parameters at 24 Months Low Incidence of Treatment Induced Anti-Drug Antibodies which Reversed Entirely Following 12 Months of Treatment without Recurrence CARMIEL, Israel, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), announced today that positive results from the Company...

New Horizons in Pancreatic Cancer

Houston, Texas – Advanced pancreatic cancer is a very tough disease to treat, so it is not surprising that by…

Owlstone Medical Raises $15 Million USD (£11 million GBP) To Drive Commercialization of Its ...

Funding round co-led by new investor Horizons Ventures and existing investor Aviva Read more...

VIDEO: Glaucoma 360 highlights innovation in glaucoma

SAN FRANCISCO ― At the Glaucoma 360: New Horizons Forum, Adrienne L. Graves, PhD, and Andrew G. Iwach, MD, co-chairs of Glaucoma 360, discuss innovations presented at the meeting and the 3 days of events that comprise the conference.

VIDEO: Heidelberg showcases Spectralis at Glaucoma 360

SAN FRANCISCO ― At the Glaucoma 360: New Horizons Forum, Kfir Azoulay, vice president and head of corporate strategy at Heidelberg Engineering, discusses the Spectralis imaging platform.

Carmot brings in $15mm via Series B

Carmot Therapeutics Inc. raised $15mm through its Series B financing led by first-time backer Horizons Ventures and returning...

VIDEO: Santen reaffirms commitment to glaucoma treatment

SAN FRANCISCO ― At the Glaucoma 360: New Horizons Forum, Ram Palanki, PharmD, senior vice president of the Americas commercial for Santen, discusses the company’s pipeline in glaucoma therapy and clinical trials taking place globally.

VIDEO: New class of therapies may offer neuroprotection, pressure lowering

SAN FRANCISCO ― At the Glaucoma 360: New Horizons Forum, Jeffrey L. Goldberg, MD, PhD, professor and chair of ophthalmology at the Byers Eye Institute at Stanford University, discusses new glaucoma therapies that show promise to not only lower IOP but also provide neuroprotection.

The human body's golden gate to iron traffic

New findings could change how iron metabolism in the human body is understood, and open new horizons for research and therapeutics for inflammatory diseases and neurodegenerative diseases, such as Alzheimer’s and Parkinson's disease.

Tetra Bio-Pharma Inc.: Tetra Bio-Pharma Added to Leading Cannabis ETF: Horizons Marijuana Life Sciences Index

OTTAWA, ONTARIO -- (Marketwired) -- 03/20/18 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discover...

VIDEO: Aerie ramps up marketing for Rhopressa

SAN FRANCISCO ― At the Glaucoma 360: New Horizons Forum, Tom Mitro, president and chief operating officer of Aerie Pharmaceuticals, discusses the build-out the company is performing to ramp up for the commercial launch of Rhopressa for the treatment of glaucoma and gives an update on clinical trials of Roclatan.

Next-generation ‘active genetics’ tool opens new horizons

In 2015, University of California San Diego biologists Ethan Bier and Valentino Gantz developed a breakthrough technology known as "active genetics," which results in parents transmitting a genetic trait to most of their offspring (instead of 50 percent receiving the trait under standard inheritance).

VIDEO: Interventional glaucoma treatment: A needed paradigm shift

SAN FRANCISCO ― Ike K. Ahmed, MD, kicked off the Glaucoma 360: New Horizons Forum with the Drs. Henry and Frederick Sutro Memorial Lecture, in which he talked about interventional glaucoma treatment ushering in a new and disruptive approach to glaucoma treatment.

Bonterra Extends Multiple Zones at Gladiator Gold Deposit

Bonterra continues to advance the development of the Gladiator Gold Deposit through definition drilling across all mineralized horizons. Follow up on previous step-out drilling has Read more...

VIDEO: nGoggle allows assessment of brain function using virtual reality

SAN FRANCISCO ― At the Glaucoma 360: New Horizons Forum, Felipe Medeiros, MD, PhD, professor of ophthalmology at Duke University, discusses the development of the nGoggle, a device that merges virtual reality goggle technology with electroencephalogram technology to help assess visual function.

VIDEO: MicroPulse technology reduces IOP in wide range of glaucomatous eyes

SAN FRANCISCO ― At the Glaucoma 360: New Horizons Forum, Shan Lin, MD, talks about a study he and colleagues at UCSF have initiated, using Iridex's MicroPulse laser technology in transscleral cyclophotocoagulation in patients with a range of mild to refractory glaucoma. The technology has so far successfully lowered IOP 20% or more in 68% of eyes treated, he said.

Probably Relevant

Informed Consent Conundrum: Making the Complex Concise

New language regarding informed consent in the revised Common Rule seems benign enough at first reading, but actually accomplishing the directives in a scientifically valid manner is a formidable undertaking.

Finding a Path to Informed Consent for the Addicted

As an opioid epidemic ravages the country, a cutting-edge question on the frontier of neuroscience is: Can addiction be blocked in the brain? Even if it could, the question for IRBs will immediately be: Can an addict give informed consent?

Active genetics technology opens new horizons

(University of California - San Diego) Employing CRISPR/Cas9 advancements, UC San Diego researchers are using new active genetics technology to reveal new fundamental mechanisms that control gene activity. The authors also provide experimental validation for using active genetics as an efficient means for targeted gene insertion, or 'transgenesis,' and single-step replacement of genetic control el...

Tips for Simplifying Informed Consent Language

Using plain language in informed consent forms means exchanging medical and statistical jargon for words that people with low health literacy and low health numeracy would understand.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks